Juvisync Approval History
- FDA approved: Yes (First approved October 7th, 2011)
- Brand name: Juvisync
- Generic name: simvastatin and sitagliptin
- Company: Merck & Co., Inc.
- Treatment for: Diabetes, Type 2, High Cholesterol, Familial Homozygous, High Cholesterol, Familial Heterozygous, Hypertriglyceridemia
Juvisync (simvastatin and sitagliptin) is an HMG-CoA reductase inhibitor (statin) and dipeptidyl peptidase-4 (DPP-4) inhibitor fixed dose combination for the treatment of high cholesterol and type 2 diabetes.
Development History and FDA Approval Process for Juvisync
|Oct 7, 2011||FDA Approves Combination Therapy Juvisync|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.